Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial
- Posted on September 8, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial
Sept 8 (Reuters) - Amgen's targeted immunotherapy, Imdelltra, combined with AstraZeneca's cancer drug Imfinzi, significantly improved overall survival in patients with extensive-stage small-cell lung cancer in a late-stage trial, the companies said on Tuesday. Here are some details: • The trial tested the combination as a maintenance treatment against Imfinzi alone in patients whose disease had
